Zydus Lifesciences Concludes USFDA Inspection at Ankleshwar Plant
Filing Summary
Zydus Lifesciences Ltd announced the conclusion of a USFDA inspection at its Unit-2 manufacturing plant in Ankleshwar, Gujarat. The inspection took place from January 19 to January 23, 2026, resulting in three observations. Importantly, there were no data integrity-related observations. The company plans to work closely with the USFDA to address these observations promptly. This disclosure aligns with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Zydus Lifesciences Ltd has reported the completion of a USFDA inspection at its Unit-2 manufacturing plant located in Ankleshwar, Gujarat. The inspection was conducted over a period from January 19 to January 23, 2026.
The inspection concluded with three observations. Notably, there were no observations related to data integrity. Zydus Lifesciences has stated its intention to work closely with the USFDA to address these observations in an expedited manner.
This update is provided in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Zydus Lifesciences Ltd is a pharmaceutical company focused on the development, manufacturing, and marketing of a wide range of healthcare products. The company prioritizes innovation and quality in its operations, aiming to meet global healthcare needs through its diverse product portfolio.